Molecular Analysis for Therapy Choice (MATCH)

Study Overview

This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

Study Description

The purpose of this study is to evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas/multiple myeloma.

Additional Information

Participants will not be paid for their participation.

  • IRB Number: 1506163289 (EAY131/MATCH)
  • Research Study Identifier: TX5399
  • Principal Investigator: Kathy Miller, MD

Recruitment Status

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at or by phone at (888) 264-0005.